Literature DB >> 25078746

[Clinical research XXII. From clinical judgment to Cox proportional hazards model].

Marcela Pérez-Rodríguez1, Rodolfo Rivas-Ruiz, Lino Palacios-Cruz, Juan O Talavera.   

Abstract

Survival analyses are commonly used to determine the time of an event (for example, death). However, they can be used also for other clinical outcomes on the condition that these are dichotomous, for example healing time. These analyses only consider the relationship of one variable. However, Cox proportional hazards model is a multivariate analysis of the survival analysis, in which other potentially confounding covariates of the effect of the main maneuver studied, such as age, gender or disease stage, are taken into account. This analysis can include both quantitative and qualitative variables in the model. The measure of association used is called hazard ratio (HR) or relative risk ratio, which is not the same as the relative risk or odds ratio (OR). The difference is that the HR refers to the possibility that one of the groups develops the event before it is compared with the other group. The proportional hazards multivariate model of Cox is the most widely used in medicine when the phenomenon is studied in two dimensions: time and event.

Entities:  

Keywords:  Hazard ratio; Multivariate models; Survival

Mesh:

Year:  2014        PMID: 25078746

Source DB:  PubMed          Journal:  Rev Med Inst Mex Seguro Soc        ISSN: 0443-5117


  1 in total

1.  Biochemical relapse free survival rate in patients with prostate cancer treated with external radiotherapy: outcomes obtained at the CMN Siglo XXI Hospital de Oncología, CMN 20 de Noviembre and Hospital General de México of the México City.

Authors:  Christian Adame González; José Trinidad Álvarez Romero; Mario Morachel Y Rodríguez; Armando Félix Leyva; Mario Ponce Viveros; Michelle Aline Villavicencio Queijeiro; María Yicel Bautista Bautista Hernández; Leticia Gracia-Medrano Valdemar
Journal:  Rep Pract Oncol Radiother       Date:  2020-02-21
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.